13 completed, 5 unknown, 4 terminated, 2 not yet recruiting. 27 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 27 | Completed 13, Unknown 5, Terminated 4, Not yet recruiting 2, Active not recruiting 1, Enrolling by invitation 1, Recruiting 1 |
Follow Hyperkalemia: new trials by email Literature Review of Hyperkalemia trials Research Report on Hyperkalemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study Finerenone, Spironolactone (drug) - Heart Failure, Diabetic Kidney Disease | Phase 4 | Not yet recruiting | Hospital de Messejana Dr. Carlos Alberto Studart Gomes | 60 | 2026-04-01 | 2026-05-13 |
| the Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients Sodium Zirconium Cyclosilicate (SZC) - Chronic Kidney Disease on Hemodialysis, Hypokalemia | Phase 4 | Not yet recruiting | Qianfoshan Hospital | 100 | 2025-03-01 | 2024-12-16 |
| Sodium Zirconium Cyclosilicate to Allow Liberal Fruit and Vegetable Intake for Patients With CKD Stage 3b and 4 Sodium zirconium cyclosilicate - Hyperkalemia, Diet Modification | Phase 4 | Unknown | Leiden University Medical Center | 16 | 2024-04-29 | 2025-03-06 |
| Potassium Correction for RAAS Optimization in Chronic Kidney Disease Patiromer 8400 MG [Veltassa], Placebo - Chronic Kidney Diseases, Hyperkalemia | Phase 4 | Recruiting | University Medical Center Groningen | 44 | 2024-04-01 | 2025-12-19 |
| 5 Versus 10 Units of Insulin in Hyperkalemia Management Insulin regular, Dextrose 50, salbutamol - Hyperkalemia, Potassium Imbalance | Phase 4 | Completed | Oman Medical Speciality Board | 384 | 2023-10-01 | 2025-12-22 |
| A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia LOKELMA 5 GM Powder for Oral Suspension - Hyperkalemia | Phase 4 | Completed | NephroNet, Inc. | 88 | 2022-04-14 | 2024-06-05 |
| Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study Sodium Zirconium Cyclosilicate (SZC), Local standard of care - Hyperkalaemia, Chronic Kidney Disease | Phase 4 | Completed | AstraZeneca | 186 | 2022-03-24 | 2025-11-28 |
| The Effect of Potassium Lowering Drugs on Cardiac Electrical Stability in Hemodialysis Patients (ART Study) sodium zirconium cyclic silicate - Potassium Imbalance, Cardiac Arrhythmia | Phase 4 | Unknown | Peking University First Hospital | 61 | 2022-02-14 | 2024-02-05 |
| Occurrence of Dyskalemia With Treatment for Hypertension Fixed Dose Combination pill of Telmisartan 40mg and Amlodipine 5 mg - Hypertension, Potassium Imbalance | Phase 4 | Completed | National Heart Foundation of Bangladesh | 1090 | 2022-01-15 | 2023-07-14 |
| Levalbuterol Compared to Albuterol Regarding Cardiac Side Effects and Potassium Lowering Effects. Levalbuterol, Albuterol - Hyperkalemia | Phase 4 | Unknown | University of Aleppo | 30 | 2021-11-04 | 2021-12-30 |
| Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients Patiromer Oral Product - Hyperkalemia, Kidney Transplant | Phase 4 | Completed | Oslo University Hospital | 13 | 2021-09-01 | 2023-03-23 |
| Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia Sodium Zirconium Cyclosilicate (SZC), Enhanced dietary advice, Standard dietary advice including K+ restriction. - Hyperkalaemia | Phase 4 | Terminated | AstraZeneca | 3 | 2021-08-17 | 2023-01-19 |
| Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone Sodium zirconium cyclosilicate, Placebo, Spironolactone - Hyperkalaemia, Heart Failure With Reduced Ejection Fraction | Phase 4 | Completed | AstraZeneca | 366 | 2021-03-08 | 2025-07-09 |
| Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management Patiromer Powder for Oral Suspension [Veltassa], Placebo - Hyperkalemia | Phase 4 | Terminated | Comprehensive Research Associates | 115 | 2020-10-08 | 2023-08-31 |
| Insulin Dextrose Infusion vs Nebulized Salbutamol vs Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia Salbutamol, Insulin Aspart - Hyperkalemia | Phase 4 | Completed | Nantes University Hospital | 419 | 2019-12-20 | 2026-05-14 |
| The Effect of Sodium Zirconium Cyclosilicate on Albuminuria in Patients With Type 2 Diabetes and Hyperkalemia LOKELMA 5 GM Powder for Oral Suspension, Placebos - Type 2 Diabetes Mellitus With Kidney Complications | Phase 4 | Unknown | Steno Diabetes Center Copenhagen | 20 | 2019-10-01 | 2019-10-16 |
| Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients Patiromer Oral Powder Product - Hyperkalemia, End Stage Renal Disease | Phase 4 | Completed | Duke University | 36 | 2019-06-20 | 2025-05-30 |
| Targeted Potassium Levels for Prevention of ICD Therapy Targeted serum potassium level - Ventricular Arrhythmias and Cardiac Arrest, Implantable Defibrillator User | Phase 4 | Active not recruiting | Copenhagen University Hospital, Rigshospitalet | 1200 | 2019-03-01 | 2025-05-09 |
| Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On Spironolactone - Type2 Diabetes, Hyperkalemia | Phase 4 | Terminated | University Hospitals Cleveland Medical Center | 8 | 2018-07-17 | 2022-05-16 |
Showing 20 of 27. Sign in to see all of them.
Renal Insufficiency, Chronic (8) · Hypokalemia (3) · Albuminuria (2) · Diabetic Nephropathies (2) · Hypertension (2) · Insulin Resistance (2) · Kidney Failure, Chronic (2) · Arrhythmias, Cardiac (1) · Ascites (1) · Atrial Fibrillation (1) · Cardio-Renal Syndrome (1) · Diabetes Mellitus, Type 2 (1) · Emergencies (1) · Fibrosis (1)
Metabolic Diseases (27) · Nutritional and Metabolic Diseases (27) · Water-Electrolyte Imbalance (27) · Pathological Conditions, Signs and Symptoms (14) · Pathologic Processes (13) · Disease Attributes (11) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Kidney Diseases (11) · Male Urogenital Diseases (11) · Urogenital Diseases (11) · Urologic Diseases (11) · Chronic Disease (10) · Renal Insufficiency (10) · Cardiovascular Diseases (5)
patiromer (6) · Spironolactone (5) · sodium zirconium cyclosilicate (5) · Suspensions (4) · Albuterol (3) · Insulin (2) · Telmisartan (2) · finerenone (2) · polystyrene sulfonic acid (2) · (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol (1) · Amlodipine (1) · Bulk Drugs (1) · Canagliflozin (1) · Captopril (1) · Enalapril (1)
AstraZeneca (3) · Baylor Research Institute (1) · Comprehensive Research Associates (1) · Copenhagen University Hospital, Rigshospitalet (1) · Duke University (1) · Hospital de Messejana Dr. Carlos Alberto Studart Gomes (1) · Leiden University Medical Center (1) · Maisonneuve-Rosemont Hospital (1) · NYU Langone Health (1) · Nantes University Hospital (1) · National Heart Foundation of Bangladesh (1) · NephroNet, Inc. (1) · Oman Medical Speciality Board (1) · Oslo University Hospital (1) · Peking University First Hospital (1)
United States (11) · Netherlands (3) · Canada (2) · Denmark (2) · France (2) · Italy (2) · Spain (2) · United Kingdom (2) · Bangladesh (1) · Belgium (1) · Brazil (1) · Chile (1) · China (1) · Czechia (1) · Hungary (1)
Aaltje Adema, dr. (1) · Baraa Shebli, M.D. (1) · Christian Joens, MD, PhD (1) · David Goldfarb, MD (1) · Eric Wittbrodt, PharmD, MPH (1) · Fazilatunnesa Malik, MBBS, FCPS (1) · Femke Waanders, dr. (1) · Henning Bundgaard, Prof., DMSc (1) · Henrik Rasmussen, MD (1) · James Tumlin, MD (1) · Jeremy Whitson, BS (1)
PMID 32588430, PMID 12873814, PMID 19570764, PMID 28993507, PMID 32847923, PMID 33107592, PMID 37308268, PMID 37398685, PMID 37467227, PMID 38878009, PMID 39566872, PMID 40879429, PMID 41437987, PMID 41730555, PMID 41923135
2019 (1), 2023 (1)